S.N. 10/036,819

Atty. Dkt. No. 032026-0700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant:

Hayes et al.

Title:

Use of Biologically Active Vitamin D Compounds for the Prevention

and Treatment of Inflammatory

**Bowel Disease** 

Appl. No.:

10/036,819

Filing

12/21/2001


Date:

Examiner:

S. N. Qazi

Art Unit:

1616



## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.56

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

04/23/2003 CCHAU1

00000053 502350 10036819

01 FC:1806

180.00 CH

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.113, or an action that otherwise closes prosecution in the application.

## RELEVANCE OF EACH DOCUMENT

Each of the documents are in English. Each of the non-patent documents listed in the accompanying Form PTO-1449 was listed in the enclosed Notice of References Cited in an Office Action dated April 4, 2003, for a corresponding U.S. patent application. The single patent document listed in the Notice of References Cited is the issued U.S. patent from which this application claims priority.

Applicants respectfully request that each of the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

## <u>FEE</u>

The Commissioner is hereby authorized, in accordance with 37 CFR §§ 1.16-1.17, to charge the fee of \$180.00 as set forth in 37 CFR §1.97(c) and 37 CFR §1.17(p) in connection with submission of a supplemental information disclosure statement to Deposit Account No. 50-2350.

Respectfully submitted,

Date

FOLEY & LARDNER

Customer Number: 23524

PATENT TRADEMARK OFFICE

Telephone: (608) 258-4281 Facsimile: (608) 258-4258

Bv

Bernard P. Friedrichsen Attorney for Applicant Registration No. 44,689